<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GEMIFLOXACIN</span><br/>(gem-i-flox'a-cin)<br/><span class="topboxtradename">Factive<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">quinolone</span><br/><b>Prototype: </b>Ciprofloxacin HCl<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>320 mg tablet</p>
<h1><a name="action">Actions</a></h1>
<p>Gemifloxacin inhibits bacterial DNA gyrases, enzymes essential in replication, transcription, and repair of bacterial DNA.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Gemifloxacin is active against a wide range of gram-positive and gram-negative bacteria. Gemifloxacin has greater activity
         against gram-positive cocci and against penicillin- and ciprofloxacin-resistant <i>Streptococcus pneumoniae</i> than other fluoroquinolones.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of acute exacerbations of chronic bronchitis, mild to moderate community-acquired pneumonia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Acute sinusitis, UTI, acute pyelonephritis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to gemifloxacin or other fluoroquinolone antibiotics; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of QT interval prolongation, hypokalemia, hypomagnesia, or concurrent use of Class IA or III antiarrhythmic agents;
         bradycardia, acute myocardial ischemia; concurrent use of other medications that may prolong the QT interval; central nervous
         system disorders such as epilepsy; glucose 6-phosphate dehydrogenase deficiency; tendonitis, elderly, concurrent use of corticosteroids;
         lactation; children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Exacerbation of Chronic Bronchitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 320 mg q.d. <small>x</small> 5 d<br/><br/><span class="indicationtitle">Community Acquired Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 320 mg q.d. <small>x</small> 7 d<br/><br/><span class="indicationtitle">Sinusitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 320 mg q.d. <small>x</small> 10 d<br/><br/><span class="indicationtitle">UTI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 320 mg q.d. <small>x</small> 3 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <img src="../images/special/lesserorequal.gif"/>40 mL/min: 160 mg q.d.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 2 h before/3 h after drugs containing aluminum, magnesium, iron, zinc, or buffered tablets of any type.</li>
<li>Give at least 2 h before sucralfate.</li>
<li>Store at 15°30° C (59°86° F) and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, elevated liver enzymes. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification"> antacids</span>, <b>didanosine (tablets and powder), iron, sevelamer, sulcralfate</b> decrease absorption; may prolong the QT interval with <b>amiodarone, bretylium, disopyramide, dofetilide, ibutilide, quinidine, procainamide, sotalol</b> leading to arrhythmias; may augment photoxicity of <span class="classification">retinoids</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 71% absorbed. <span class="typehead"> Peak:</span>  0.52 h. <span class="typehead">Metabolism:</span> Minimally metabolized in liver. <span class="typehead">Elimination:</span> Primarily renal. <span class="typehead">Half-Life:</span> 7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiac status, especially with concurrent use of drugs that may prolong the QT interval. Report immediately bradycardia
            or S&amp;S of heart failure.
         </li>
<li>Withhold drug and report to physician any of the following: tremors, restlessness, lightheadedness, confusion, hallucinations,
            paranoia, depression, nightmares, and insomnia.
         </li>
<li>Lab tests: C&amp;S prior to initiation of therapy; baseline and periodic serum electrolytes; frequent blood glucose levels in
            diabetics; CBC with differential and platelet count with prolonged treatment.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use sunscreen and protective clothing outdoors. Avoid sun lamps.</li>
<li>Stop gemifloxacin and notify physician for pain or swelling of a tendon or around a joint.</li>
<li>Drink fluid liberally (unless contraindicated) while taking this drug. </li>
<li>Do not drive or engage in other hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>